

## Methodological Note: Kyowa Kirin Ltd (UK and Ireland)

Kyowa Kirin Limited (KKL) is committed to supporting healthcare and the development of patient care across the UK and Ireland. As such we are pleased to offer support to the organisations and practitioners central to making this happen. The support of Healthcare Organisations (HCOs) or Healthcare Practitioners (HCPs) and Other Relevant Decision Makers (ORDMs) through the provision of funds or services is essential to this. In accordance with industry regulations KKL publishes full details about transfers of value to these individuals and organisations, annually.

The data disclosed here pertains to 'transfers of value' (TOV) where the term means a direct or indirect transfer of value, whether in cash, in kind or otherwise, made, whether for promotional purposes or otherwise, in connection with the development or sale of medicines. A direct transfer of value is one made directly by a company for the benefit of a recipient. An indirect transfer of value is one made on behalf of a company for the benefit of a recipient or through an intermediate and where the company knows or can identify the recipient that will benefit from the transfer of value.

For direct transfers of value, the recipient is considered to be the person or entity holding the bank account receiving the money.

In the case of payments that are made through Clinical Research Organisations, these are included under Research and Development and reported in the aggregate

Where a third party has been appointed by an HCO to manage an event, and where the HCO benefits from the transfer of value, these transfers of value are disclosed against the HCO.

Where third parties are appointed by KKL to make travel and accommodation arrangements for HCPs, the transfers of value are reported against the HCP who received the benefit.

Where services were provided to an HCO by means of the provision of an individual (e.g. a pharmacist) the value of those services has been calibrated using the pay scale banding appropriate to that individual's training, experience and qualifications.

KKL has made best efforts to capture and report all transfers of value to HCPs and HCOs with primary practice in a country with EFPIA Disclosure Code or other transparency reporting requirements. The country of disclosure is based on the HCP's principal practice or the HCO's country of registration.

This disclosure excludes the following transfers of value:

- Hospitality cost (e.g. meals and drinks) unless these are an integral part of contributions to the cost of events.
- Logistical costs related to KKL-organised meetings (e.g. room hire).

TOVs are tracked for activities as defined by the relevant sections of the applicable national industry Codes (the Association of the British Pharmaceutical Industry Code of Practice and/or the Irish Pharmaceutical Healthcare Association Code of Standards).

Internal procedures are in place to capture TOVs from the following areas:

- Joint working;
- Donations, grants and benefits in kind provided to institutions, organisations and associations with regards to medical and educational goods and services;
- Contracts between Kyowa Kirin and institutions, organisations or associations of health professionals under which such institutions, organisations or associations provide any type of services for or on behalf of Kyowa Kirin conducted in line with national industry Code(s) (defined above);
- Sponsorship of attendance by health professionals and other relevant decision makers at meetings, or registration fees to access on-line medical educational training;
- Fees and expenses paid to health professionals and other relevant decision makers, or to their employers on their behalf for consultancy work conducted in line with national industry Code(s) (defined above);
- Contributions toward the costs of meetings paid to healthcare organisations or to third parties managing events on their behalf, which may include sponsorship of health professionals by way of registration fees, accommodation and/or travel.

The attached declarations cover the period from 1st January 2018 to 31st December 2018. These dates have been defined with relation to when the TOV was received by the HCO, HCP or ORDM.

All United Kingdom TOVs disclosed are in Pounds Sterling. All Ireland TOVs disclosed are in Euros.

Where payments were made in Euros, US Dollars and United Arab Emirates Dirham (AED) converted to Sterling at point of payment the sterling amount recorded has been disclosed as the TOV. Where this conversion was not made at point of payment the year end Euro rate (£1 to €1.109), US Dollar rate (£1 to \$1.269) and AED rate (£1 to AED 4.6604) has been used.

TOVs to HCOs have been disclosed on a per activity basis. Where more than one HCO benefits from the same TOV this has been divided accordingly.

Details of HCP/ORDM TOVs have only been line listed where consent has clearly and unambiguously been granted to do so. Where consent was not given or where the individual's wishes were not clearly stated they have been included in the aggregated figures provided.

Recipients who have questions regarding their consent status or any other aspect of the Disclosure should see the Kyowa Kirin Privacy Notice.

Any general questions regarding these declarations should be directed to UK and Ireland Medical Affairs (telephone (+44 (0)1896 664000 or [medicalaffairs@kyowakirin.com](mailto:medicalaffairs@kyowakirin.com)).